首页> 美国卫生研究院文献>other >Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer
【2h】

Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer

机译:外周血单个核细胞中miRNA的差异表达对肺癌的诊断

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tremendous efforts have been made to develop cancer biomarkers by detecting circulating extracellular miRNAs directly released from tumors. Yet none of the cell-free biomarkers has been accepted to be used for early detection of non-small cell lung cancer (NSCLC). Peripheral blood mononucleated cells (PBMCs) act as the first line of defense against malignancy in immune system, their dysfunction may occur as an early event in cancer immunogenicity or immune evasion. We proposed to investigate if analysis of miRNA expressions of PBMCs has diagnostic value for NSCLC. We first used a microarray to analyze PBMCs of 16 stage I NSCLC patients and 16 cancer-free smokers, and identified seven PBMC miRNAs with a significantly altered expression level in NSCLC patients. In a training set of 84 NSCLC patients and 69 cancer-free smokers, a panel of two miRNAs (miRs-19b-3p and -29b-3p) were developed from the seven PBMC miRNAs, producing 72.62% sensitivity and 82.61% specificity in identifying NSCLC. Furthermore, the miRNAs could identify squamous cell lung carcinoma (SCC), a major type of NSCLC, with 80.00% sensitivity and 89.86% specificity. The expression levels of the miRNAs were independent of disease stage. In a testing set of 56 NSCLC patients and 46 controls, the performance of the biomarkers was reproducibly confirmed. The study presents the first in-depth analysis of PBMC miRNA profile of NSCLC patients. The assessment of PBMC miRNAs may provide a new diagnostic approach for the early detection of NSCLC.
机译:通过检测直接从肿瘤释放的循环细胞外miRNA,已做出巨大努力来开发癌症生物标志物。然而,没有一种无细胞生物标志物尚未被接受用于非小细胞肺癌(NSCLC)的早期检测。外周血单核细胞(PBMC)是抵抗免疫系统恶性肿瘤的第一道防线,其功能障碍可能是癌症免疫原性或免疫逃避的早期事件。我们提议调查PBMC的miRNA表达分析是否对NSCLC具有诊断价值。我们首先使用微阵列分析了16例I期NSCLC患者和16名无癌吸烟者的PBMC,并鉴定了7种PBMC miRNA,它们在NSCLC患者中的表达水平明显改变。在由84名NSCLC患者和69名无癌吸烟者组成的训练集中,从七个PBMC miRNA中开发了一组两个miRNA(miRs-19b-3p和-29b-3p),产生72.62%的敏感性和82.61%的特异性非小细胞肺癌。此外,miRNA可以以80.00%的敏感性和89.86%的特异性鉴定出NSCLC的主要类型鳞状细胞肺癌(SCC)。 miRNA的表达水平与疾病阶段无关。在一组测试的56名NSCLC患者和46名对照中,可重复地确认了生物标志物的性能。该研究首次对NSCLC患者的PBMC miRNA谱进行了深入分析。 PBMC miRNA的评估可能为NSCLC的早期检测提供一种新的诊断方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号